Mediwound Ltd (MDWD) Shares Sold by United Services Automobile Association

United Services Automobile Association reduced its holdings in Mediwound Ltd (NASDAQ:MDWD) by 5.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 198,587 shares of the biopharmaceutical company’s stock after selling 10,855 shares during the quarter. United Services Automobile Association owned approximately 0.73% of Mediwound worth $806,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Sargent Investment Group LLC acquired a new position in Mediwound in the fourth quarter valued at $55,000. ETF Managers Group LLC increased its stake in Mediwound by 57.4% in the fourth quarter. ETF Managers Group LLC now owns 48,085 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 17,531 shares during the last quarter. Worth Venture Partners LLC acquired a new position in Mediwound in the third quarter valued at $306,000. Nexthera Capital LP increased its stake in Mediwound by 288.3% in the third quarter. Nexthera Capital LP now owns 173,076 shares of the biopharmaceutical company’s stock valued at $1,064,000 after purchasing an additional 128,500 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Mediwound by 37.4% in the third quarter. Renaissance Technologies LLC now owns 179,300 shares of the biopharmaceutical company’s stock valued at $1,103,000 after purchasing an additional 48,800 shares during the last quarter. Hedge funds and other institutional investors own 29.86% of the company’s stock.

MDWD has been the subject of several research analyst reports. Oppenheimer set a $15.00 price target on Mediwound and gave the stock a “buy” rating in a research note on Tuesday, January 22nd. Zacks Investment Research lowered Mediwound from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 16th.

NASDAQ:MDWD traded up $0.39 on Friday, hitting $4.84. 88,797 shares of the stock were exchanged, compared to its average volume of 95,817. The firm has a market capitalization of $131.55 million, a PE ratio of -9.88 and a beta of 0.69. Mediwound Ltd has a fifty-two week low of $3.76 and a fifty-two week high of $7.35.

Mediwound (NASDAQ:MDWD) last announced its quarterly earnings results on Monday, March 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.09. The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.80 million. Mediwound had a negative return on equity of 398.49% and a negative net margin of 31.08%. As a group, research analysts predict that Mediwound Ltd will post -0.57 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/united-services-automobile-association-has-806000-stake-in-mediwound-ltd-mdwd.html.

Mediwound Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: Day Trading

Institutional Ownership by Quarter for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.